Stock data
| Market cap. | NIS74.5m |
| Last close | NIS0.56 |
| High / Low (52 weeks) | NIS0.9 / NIS0.3 |
| Stock market listing | Tel Aviv Stock Exchange |
| Forecast net cash (NISm) | 15.5 |
| Forecast gearing ratio (%) | N/A |
| Team | Healthcare |
| Sector | Pharmaceutical & healthcare |
Price performance
| % | 1m | 3m | 12m |
|---|---|---|---|
| Actual | 4.3 | 72.2 | (39.8) |
| Relative * | 2.4 | 70.7 | (42.9) |
* % Relative to local index
Other companies in sector Show
Company news
Israel's CollPlant to improve 3D bioprinted organs following $5M investment ...Fri, 20 Oct 2017 09:33:45 GMT |
CollPlant jumps on EU wound gel approvalTue, 23 Feb 2016 10:11:20 GMT |
$5 million funding regenerates CollPlant's 3D printed organ development plansFri, 20 Oct 2017 16:07:30 GMT |
CollPlant establish division for 3D printing with the most abundant protein in ...Thu, 11 May 2017 21:06:00 GMT |
Israel's CollPlant Files for $25M IPO (CLGN)Thu, 27 Oct 2016 16:18:45 GMT |
| Y/E Dec | Revenue (NISm) | EBITDA (NISm) | PBT (NISm) | EPS (NIS) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2015A | 0.0 | (18.0) | (18.7) | (22.03) | N/A | N/A |
| 2016A | 0.3 | (27.0) | (27.9) | (27.72) | N/A | N/A |
| 2017E | 1.2 | (18.8) | (19.6) | (14.97) | N/A | N/A |
| 2018E | 2.7 | (17.6) | (18.2) | (13.96) | N/A | N/A |
Last updated on 18/09/2017
Latest research
Fund-raising should enable strategic delivery
Update | Pharmaceutical & healthcare | 18/09/2017
Continuing to build on 2016
Update | Pharmaceutical & healthcare | 05/06/2017
Good progress in 2016
Update | Pharmaceutical & healthcare | 04/04/2017
Solid foundations with potential for growth
Initiation | Pharmaceutical & healthcare | 09/03/2017
המחקר העדכני ביותר
קולפלנט אחזקות
קולפלנט אחזקות
05/06/2017
Investment summary
CollPlant’s investment story is built on the versatility of its plant-based technology, rhCollagen, and its application in regenerative medicine. It has strong potential across various subsectors, initially focusing on orthobiologics, advanced wound care and 3D printing of tissue and organs. Two products have recently been launched: VergenixFG, targeting chronic and acute wounds, and VergenixSTR, targeting tendinopathy. 2016 was an important year for CollPlant as it completed a clinical study and received its CE approval for VergenixSTR, entered into an exclusive distribution agreement with Arthrex to commercialise VergenixSTR in EMEA and launched VergenixFG in Europe. We expect CollPlant to build on this progress in 2017 by increasing its distribution of VergenixFG and orders from Arthrex, alongside developing its earlier-stage rhCollagen technology BioInk for 3D printing of organs and tissues. Recent announcement of a $5m placing leaves the company well-financed to progress.
Last updated on 03/10/2017
Industry outlook
Orthobiologics and advanced wound care are substantial growing markets and are estimated to be worth $6.7bn (according to GlobalData) and $8.5bn (according to Smith & Nephew) respectively.
Last updated on 03/10/2017
Key management
| Yehiel Tal, CEO |
| Eran Rotem, CFO |
Company address
| 3 Sapir Street Weizmann Science Park, P.o.B 4132 Ness-Ziona Nes Ziona 74140 Israel 972-73-232-5600 View website |